Lifeboat Foundation

Better treatments are definitely on the way.

Nanomedicines took the spotlight during the COVID-19 pandemic. Researchers are using these very small and intricate materials to develop diagnostic tests and treatments. Nanomedicine is already used for various diseases, such as the COVID-19 vaccines and therapies for cardiovascular disease. The “nano” refers to the use of particles that are only a few hundred nanometers in size, which is significantly smaller than the width of a human hair.

NIH Image Gallery/Flickr.

Continue reading “How these factors could lead to better nanomedicine treatments” »

Let me pick up where I left off ahead of Christmas by reiterating the fives themes for 2023 (‘War by Other Means’) that I had put together with David Skilling. The note details the trends we expect to materialise through the year as intense strategic competition between regions takes hold.

ChatGPT brings AI into our everyday lives, highlighting also its use in many other domains such as medicine and justice.

We’ve met with Mojo Vision for several CESes, watching the startup’s AR contact lenses develop, year by year. These sorts of things take a lot of time and money, of course — and these days it seems increasingly difficult to find either. Today, the California-based firm announced that it is “decelerating” work on the Mojo Lens, citing, “significant challenges in raising capital.”

In an announcement posted to it site, CEO Drew Perkins blames insurmountable headwinds, including the bad economy and the “yet-to-be proven market potential for advanced AR products” in its ability to raise the necessary funding required to keep the project afloat.

“Although we haven’t had the chance yet to see it ship and to reach its full potential in the marketplace, we have proven that what was once considered science fiction can be developed into a technical reality,” Perkins writes. “Even though the pursuit of our vision for Invisible Computing is on hold for now, we strongly believe that there will be a future market for Mojo Lens and expect to accelerate it when the time is right.”

Heparin has long been used as a blood thinner, or anticoagulant, for patients with blood clotting disorders or after surgery to prevent complications. But the medication remains difficult to dose correctly, potentially leading to overdosing or underdosing.

A team of Penn State researchers combined heparin with a protein fragment, peptide, to slow down the release of the drug and convey the medication directly to the site of a clot. They published their findings in the journal Small.

“We wanted to develop a material that can gradually deliver heparin over time rather than the current iteration that gets cleared from the body in a couple of hours,” said corresponding author Scott Medina, Penn State associate professor of biomedical engineering. “We also wanted to deliver the drug through the skin instead of through an IV.”

A new drug that contains an ACE2 decoy molecule may be the way we stop COVID-19 permanently.

What’s Needed is a New Approach

A recent paper appearing in Science Advances published on December 7, 2022, describes a new approach to tackling COVID-19. A new drug in animal trials has shown effectiveness in stopping the spread of coronaviruses and all variants. It is the way this drug works that gives it a unique advantage not just to stop present Omicron and other COVID-19 versions but all future evolutions of the virus and other coronaviruses.

Continue reading “COVID-19 Defence May Soon Have a New Weapon In Our Collective Arsenal” »

Join us on Patreon!
https://www.patreon.com/MichaelLustgartenPhD

Bristle Discount Link (Oral Microbiome Quantification):
ConquerAging15
https://www.bmq30trk.com/4FL3LK/GTSC3/

Continue reading “Attempting To Optimize The Oral Microbiome, Part 3: A Role For Berberine” »

Great advice here. I follow much of it; my diet is good though there is a little bit of processed stuff in it. I do not drink or smoke. Interesting that Dr Stanfield has a rapamycin human trial going.

We have the tools available today to have a healthy 105-year lifespan, and I’ll summarise it all in this video. Plus at the end we’ll go through the emerging therapies in the longevity space that will push us towards a healthy 120-year lifespan.

Continue reading “How To Have A HEALTHY 105-Year Lifespan (Soon 120-Years)” »

McMaster University researcher Sheila Singh and her team have discovered how glioblastoma, a lethal brain cancer, can evade treatments and kill.

The researchers found the cancer cells that survive the first round of radiotherapy or chemotherapy do so by mutating during the post-treatment minimal residual disease (MRD) or dormant state. The MRD profile of each patient was mapped using single cell sequencing to find a genetic signature that predicted how the cancer would recur in each individual.

Singh said that by mapping the MRD, researchers found that each patient had a different trajectory to their cancer recurring, potentially opening the door to future treatments tailored to each individual with glioblastoma. Singh’s team monitored five patients between 2018 and 2022.

Powered by data produced by its AI-driven discovery platform, clinical-stage biotech BioAge Labs is rapidly developing a pipeline of therapies to extend healthy lifespan by targeting the molecular causes of aging. Having raised more than $120 million in funding, and with multiple clinical trials already under its belt, the company is focused on building a broad pipeline of potential longevity therapies in three main areas: muscle, immune, and brain aging.

Longevity. Technology: There are few companies in the longevity biotech field that appear to be executing on their vision as quickly and consistently as BioAge. When the company wowed the sector with a $90 million funding round in 2020, talk of multiple imminent clinical trials may have sounded optimistic to some, but BioAge has delivered on its promise time and again. Beyond the trials already underway, the company’s much-vaunted AI discovery platform also appears to be churning out the data, this year spawning a new programme exploring the potential of NLRP3 inhibitors in brain aging. To learn more, we caught up with BioAge co-founder and CEO Kristen Fortney.

Looking back at 2022, Fortney says it has been “immensely gratifying” to see so many new companies and investors coming into the longevity field.